From Fierce Biotech, it seems that big pharma has happily stepped into the funding void created by the collapse of venture funding for biotechs to do more deals earlier and cheaper than before. Says Dan Zabrowski, head of Roche's drug partnership unit, "We are doing around 50 to 60 partnership deals a year now, compared to around 30 deals per year before the crisis [of 2008]. Today, we start deals earlier with less upfront payments and share the risk with our partners."
Who says a funding crunch is so bad? This is not exactly a hardship for big pharma.
Posted by Bruce Lehr Dec 12th 2011.